FIELD: medicine, experimental medicine.
SUBSTANCE: starting since the 7th to the 28th d after modeling a patient's limb's ischemia it is necessary to inject L-arginine intraperitoneally at the dosage ranged 30-200 mg/kg body weight. The innovation provides optimal dosages and the mode for injecting L-arginine as NO donator.
EFFECT: higher efficiency.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY FOR CHRONIC LIMB ISCHEMIA | 2007 |
|
RU2353977C1 |
| METHOD FOR CORRECTING ENDOTHELIAL DYSFUNCTION | 2005 |
|
RU2271202C1 |
| METHOD OF ENDOTHELIAL DYSFUNCTION CORRECTION BY COMBINATION OF TRIMETAZIDINE AND L-ARGININE IN L-NAME-INDUCED NITROGEN OXIDE DEFICIENCY | 2009 |
|
RU2421822C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH SOLVENT MIXTURE OF HOMEOPATHIC DILUTIONS OF POLYCLONAL RABBIT ANTIBODIES TO HUMAN ENDOTHELIAL NITROGEN OXIDE SYNTHASE C12, C30, C200 | 2006 |
|
RU2306953C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF LOSARTAN AND L-ARGININE IN L-NAME-INDUCED NITROGEN DEFICIT | 2005 |
|
RU2306930C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF INDAPAMIDE AND L-ARGININE IN L-NAME-INDUCED NITROGEN DEFICIT | 2005 |
|
RU2306929C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY COMBINATION OF AMLODIPINE AND L-ARGININE IN L-NAME-INDUCED DEFICIENCY OF NITROGEN OXIDE | 2005 |
|
RU2296566C1 |
| METHOD OF CORRECTING ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF LOZARTAN AND RAZVERATROL IN CASES OF LONAME-INDUCED NITROGEN MONOXIDE DEFICIENCY | 2005 |
|
RU2306924C1 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH PREPARATION PHOSPHOGLIV LYOPHILIZATE IN L-NAME INDUCED NITROGEN OXIDE DEFICIENCY | 2008 |
|
RU2372078C1 |
| METHOD OF CORRECTION OF ENDOTHELIAL DYSFUNCTION BY PHOSPHOGLIV PREPARATION AT L-NAME INDUCED DEFICIENCY OF NITROGEN OXIDE | 2008 |
|
RU2359668C1 |
